For decades, a diagnosis of Sanfilippo syndrome type A came with the same brutal script: your toddler will hit their milestones, then slowly lose them — speech, memory, the ability to walk — and most likely won't reach adulthood. There was nothing to prescribe. Not one approved drug. Just a countdown.

Let's get the number on the table first: $3.95 million. That's the U.S. list price Ultragenyx set for Fayuvi, the first treatment ever cleared for this disease, approved by the FDA in mid-September (Reuters). One infusion. One time. Nearly four million dollars.

That price tag makes Fayuvi tied for the second-most-expensive gene therapy on the planet, behind only Orchard's Lenmeldy at $4.25 million (Labiotech). And it lands on a disease that, until now, had exactly zero disease-modifying options.

Here's the thesis: a fatal childhood disease finally has a treatment — and the fight over who can actually get it is only beginning.

🧠 Why This Matters

Sanfilippo syndrome type A — clinically, mucopolysaccharidosis type IIIA, or MPS IIIA — is a rare inherited disorder that progressively wrecks the brain and nervous system. Children are born looking healthy, develop normally for a while, then start losing cognitive, language, and developmental abilities. Median life expectancy is roughly 15 years (Pharmaceutical Technology).

The root cause is a broken SGSH gene, which leaves cells unable to make an enzyme called sulfamidase. Without it, cellular waste builds up and poisons neurons. Fayuvi (generic name: rebisufligene etisparvovec-hopf) is a one-time intravenous gene therapy that uses an AAV9 viral vector to ferry a working copy of SGSH into cells, so the body can start producing the missing enzyme itself (Pharmaceutical Technology).

"We recognize the profound urgency of making this therapy available to families." — Emil Kakkis, M.D., Ph.D., CEO of Ultragenyx (FiercePharma)

For the roughly 3,000 to 5,000 treatable patients in commercially accessible regions, this is the difference between a countdown and a chance.

📊 Deep Dive

The approval rests on the Transpher A trial, a Phase 1/2/3 study of 27 children — 17 treated at a younger, earlier stage of disease and 10 who were older (FiercePharma). The younger group is where the data really moved.

Against an untreated natural-history group, the earlier-treated kids showed a 23.2-point improvement on the Bayley-III cognitive scale. Eight of them reached a 36-month cognitive development age — a threshold that zero children in the natural-history comparison ever hit (FiercePharma). Older, later-stage children held onto function in at least one of three assessed areas, better than the typical decline.

Where does $3.95 million sit in the gene-therapy pricing race? Roughly here (U.S. list prices, per Labiotech):

  • Lenmeldy (metachromatic leukodystrophy) — $4.25M
  • Fayuvi (Sanfilippo type A) — $3.95M
  • Hemgenix (hemophilia B) — $3.5M
  • Elevidys (Duchenne muscular dystrophy) — $3.2M
  • Casgevy (sickle cell & beta-thalassemia) — $2.2M

Getting here wasn't clean. The FDA rejected Ultragenyx's first submission in July 2025 over manufacturing issues at its Bedford, Massachusetts facility and a third-party manufacturer (BioSpace). This is the company's second run at the finish line — and its second approved gene therapy overall.

⚠️ The Catch

A $3.95 million sticker is not what anyone pays at a pharmacy counter — but it is the number every insurer, Medicaid program, and hospital budget now has to reckon with. Ultragenyx's own commercial chief was quick to add context, noting the figure "reflects the list price before discounts, rebates or potential treatment outcomes-based reimbursement policies" (FiercePharma).

Translation: outcomes-based deals — where the company gets paid only if the therapy actually works — are likely on the table. But the coverage fights, prior-authorization mazes, and state-by-state Medicaid negotiations that follow a price like this can stretch for months.

And time is the one thing these families don't have. The trial data is clearest for children treated early, before the disease has done its damage. That puts enormous pressure on newborn screening and fast diagnosis — because a therapy that works best on the youngest patients is only as good as the system's ability to find them in time.

🎯 What Happens Next

Ultragenyx expects Fayuvi to be available at specialized U.S. treatment centers within 30 to 60 days (Reuters). J.P. Morgan analysts project peak worldwide sales of $200 million to $250 million — modest by big-pharma standards, which is exactly the economics of an ultra-rare disease: tiny patient pool, enormous per-patient price.

Watch three things: how quickly the first commercial infusions actually happen, whether payers sign outcomes-based agreements or dig in, and whether newborn-screening programs start adding MPS IIIA now that catching it early genuinely changes a child's trajectory.

🧩 Bigger Picture

Fayuvi is the latest data point in a market that keeps testing the ceiling on drug pricing. Five of the priciest medicines in the world are now one-time gene therapies, each aimed at a disease so rare that the traditional model — sell a lot, charge a little — simply doesn't apply. Instead the pitch is: pay once, fix the gene, and (in theory) never treat again.

That model works beautifully in a spreadsheet and gets very complicated in a state Medicaid office. For a family staring down a diagnosis that used to mean a 15-year countdown, though, the abstract debate collapses into something simple.

"Real hope and a real life-changing chance to have a different outcome." — Glenn O'Neill, president and co-founder of the Cure Sanfilippo Foundation (Reuters)

For thirty years, the answer to "what can we do?" was nothing. Now the answer costs $3.95 million — and for the first time, it isn't nothing.

Sources